February 15, 2018
Selumetinib granted Orphan Drug Designation by the US FDA for neurofibromatosis type 1
AstraZeneca and Merck will have a new Orphan Drug Designation in selumetinib, a MEK 1/2 inhibitor, as the US Food and…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Merck
January 4, 2018
Japan approves Merck’s Keytruda to treat patients with a type of bladder cancer
Merck’s anti PD-1 therapy Keytruda has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) to treat…
October 18, 2017
AstraZeneca and Merck said Wednesday that th eUS Food and Drug Administration (FDA) has accepted and granted priority review for a…
August 18, 2017
AZ, Merck: Lynparza gets additional and braod approval in the US for ovarian cancer
AstraZeneca’s and Merck’s Lynparza new tablet’s formulation has been approved as maintenance treatment for women with platinum-sensitive recurrent ovarian cancer regardless of BRCA-mutation status, the companies said Friday.
July 27, 2017
Merck, AstraZeneca in a $8.5 billion oncology deal
AstraZeneca and Merck on Thursday said that they have made a deal to co-develop and co-commercialise AstraZeneca’s oncology product Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.
July 4, 2017
First patients get NOX-A12 combined with Keytruda in certain cancers
NOXXON Pharma, a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, has treated first patients in its Phase 1/2 clinical trial in patients with metastatic colorectal and pancreatic cancer at the National Center for Tumor Diseases in Heidelberg, Germany.
June 29, 2017
Sales hopes for new Novartis, Merck heart drugs under microscope
Novartis and Merck have both surprised experts in the past week by finding new ways to tackle heart disease, although the jury remains out as to whether this scientific success will translate into blockbuster sales.
May 24, 2017
Merck’s Keytruda gets FDA’s approval as first cancer treatment for any solid tumor with a specific genetic feature
The U.S. Food and Drug Administration on Tuesday approved Merck’s Keytruda as a first cancer treatment for any solid tumor with a specific genetic feature.
May 19, 2017
100 Healthy Years – Are Kids Prepared?
Merck, one of the worlds most renown science and technology companies, summoned experts from worlds organizations such as UN, UNICEF, UNAIDS, World Obesity Federation and McKinsey at the the company’s headquarters in Darmstadt, Germany, to discuss questions about the most urgent threats to our children’s long-term health, or what can be done both inside and outside the classroom? And how do schools, parents and communities share responsibility?
March 2, 2017
NICE’s approval of Merck’s Erbitux combination gives more choice for mCRC patients in England
English wild-type metastatic colorectal cancer (mCRC) patients are getting more choice to a first-line effective treatment, as the UK National Institute for Health and Care Excellence (NICE) gave a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Merck’s Erbitux (cetuximab) in combination with either Folfiri or Folfox.